{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:54:59Z","timestamp":1789674899092,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.antiviral.2020.104908","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T12:19:12Z","timestamp":1597321152000},"page":"104908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Repurposing Pyramax\u00ae, quinacrine and tilorone as treatments for Ebola virus disease"],"prefix":"10.1016","volume":"182","author":[{"given":"Thomas R.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dyall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-8997","authenticated-orcid":false,"given":"Daniel H.","family":"Foil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Postnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janie Y.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-5610","authenticated-orcid":false,"given":"Peter B.","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104908_bib1","first-page":"1","article-title":"Determination of the physicochemical properties of pyronaridine - a new antimalarial drug","volume":"19","author":"Adegoke","year":"2006","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2020.104908_bib2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/acsomega.8b02948","article-title":"Ebola virus bayesian machine learning models enable new in vitro leads","volume":"4","author":"Anantpadma","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.antiviral.2020.104908_bib3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/acsomega.8b02948","article-title":"Ebola virus bayesian machine learning models enable new in vitro leads","volume":"4","author":"Anantpadma","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.antiviral.2020.104908_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/js960001i","article-title":"Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells","volume":"85","author":"Augustijns","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.antiviral.2020.104908_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2020.104908_bib6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2020.104908_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2020.104908_bib8","first-page":"249","article-title":"Assessing agreement on classification tasks: the kappa statistic","volume":"22","author":"Carletta","year":"1996","journal-title":"Comput. Ling."},{"key":"10.1016\/j.antiviral.2020.104908_bib9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/acs.jcim.5b00143","article-title":"Open source bayesian models. 1. Application to ADME\/tox and drug discovery datasets","volume":"55","author":"Clark","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2020.104908_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.jcim.5b00144","article-title":"Open source bayesian models. 2. Mining a \"big dataset\" to create and validate models with ChEMBL","volume":"55","author":"Clark","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2020.104908_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"10.1016\/j.antiviral.2020.104908_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166318","article-title":"Evaluation of the activity of lamivudine and zidovudine against Ebola virus","volume":"11","author":"Cong","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104908_bib13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104908_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","article-title":"Review of pyronaridine anti-malarial properties and product characteristics","volume":"11","author":"Croft","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.antiviral.2020.104908_bib15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1039\/c8mt00342d","article-title":"High-throughput screening and Bayesian machine learning for copper-dependent inhibitors of Staphylococcus aureus","volume":"11","author":"Dalecki","year":"2019","journal-title":"Metall"},{"key":"10.1016\/j.antiviral.2020.104908_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/jvi.2.10.955-961.1968","article-title":"Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)","volume":"2","author":"Desmyter","year":"1968","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104908_bib17","series-title":"Antiviral Screening of Multiple Compounds against Ebola Virus","author":"Dowall","year":"2016"},{"key":"10.1016\/j.antiviral.2020.104908_bib18","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1099\/jgv.0.000309","article-title":"Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model","volume":"96","author":"Dowall","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104908_bib19","doi-asserted-by":"crossref","first-page":"S592","DOI":"10.1093\/infdis\/jiy345","article-title":"In vitro and in vivo activity of amiodarone against Ebola virus","volume":"218","author":"Dyall","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib20","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","article-title":"Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures","volume":"218","author":"Dyall","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.7217.1","article-title":"Machine learning models identify molecules active against Ebola virus in vitro","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.antiviral.2020.104908_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11095-019-2671-y","article-title":"Repurposing approved drugs as inhibitors of Kv7.1 and Nav1.8 to treat pitt hopkins syndrome","volume":"36","author":"Ekins","year":"2019","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.antiviral.2020.104908_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-020-02799-8","article-title":"Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond","volume":"37","author":"Ekins","year":"2020","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.antiviral.2020.104908_bib24","article-title":"Efficacy of tilorone dihydrochloride against Ebola virus infection","volume":"62","author":"Ekins","year":"2018","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.antiviral.2020.104908_bib25","article-title":"Tilorone: a broad-spectrum antiviral for emerging viruses","volume":"64","author":"Ekins","year":"2020","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.antiviral.2020.104908_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat. Mater."},{"key":"10.1016\/j.antiviral.2020.104908_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.12688\/f1000research.6181.1","article-title":"Finding small molecules for the 'next Ebola","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.antiviral.2020.104908_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1099\/0022-1317-43-1-247","article-title":"Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production","volume":"43","author":"Emeny","year":"1979","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104908_bib29","series-title":"First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response","author":"FDA","year":"2019"},{"key":"10.1016\/j.antiviral.2020.104908_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-018-2558-3","article-title":"High throughput and computational repurposing for neglected diseases","volume":"36","author":"Hernandez","year":"2018","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"W1","key":"10.1016\/j.antiviral.2020.104908_bib31","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2020.104908_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007604","article-title":"SynToxProfiler: an interactive analysis of drug combination synergy, toxicity and efficacy","volume":"16","author":"Ianevski","year":"2020","journal-title":"PLoS Comput. Biol."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104908_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMsr1904253","article-title":"The ongoing Ebola epidemic in the democratic republic of Congo, 2018-2019","volume":"381","author":"Ilunga Kalenga","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104908_bib34","series-title":"Identification of Antiviral Drug Candidates against SARS-CoV-2 from FD-Approved Drugs","author":"Jeon","year":"2020"},{"key":"10.1016\/j.antiviral.2020.104908_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104908_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/d41586-019-02415-9","article-title":"Pandemic bonds: designed to fail in Ebola","volume":"572","author":"Jonas","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104908_bib37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2020.104908_bib38","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.molpharmaceut.8b00083","article-title":"Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery","volume":"15","author":"Lane","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2020.104908_bib39","article-title":"Repurposing quinacrine against Ebola virus infection in vivo","volume":"63","author":"Lane","year":"2019","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.antiviral.2020.104908_bib40","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus","volume":"13","author":"Lane","year":"2019","journal-title":"Infection PLoS Negl Trop Dis"},{"key":"10.1016\/j.antiviral.2020.104908_bib41","series-title":"Pyronaridine Tetraphosphate Efficacy against Ebola Virus Infection in Guinea Pig","author":"Lane","year":"2020"},{"key":"10.1016\/j.antiviral.2020.104908_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.antiviral.2020.104908_bib43","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.antiviral.2020.104908_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104908_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0005-2795(75)90109-9","article-title":"Comparison of the predicted and observed secondary structure of T4 phage lysozyme","volume":"405","author":"Matthews","year":"1975","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2020.104908_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib49","series-title":"1-Benzyl-3-cetyl-2-methylimidazolium Iodide (NH125) Is a Broad-Spectrum Inhibitor of Virus Entry with Lysosomotropic Features","author":"Moeschler","year":"2018"},{"key":"10.1016\/j.antiviral.2020.104908_bib50","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104908_bib51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.antiviral.2020.104908_bib52","first-page":"347","article-title":"Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines","volume":"55","author":"Ploemen","year":"2004","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.antiviral.2020.104908_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104908_bib54","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1021\/acs.molpharmaceut.8b00546","article-title":"Comparing multiple machine learning algorithms and metrics for estrogen receptor binding prediction","volume":"15","author":"Russo","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2020.104908_bib55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14787210.2017.1305888","article-title":"Antiviral activity of cationic amphiphilic drugs","volume":"15","author":"Salata","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2020.104908_bib56","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1124\/mol.117.111443","article-title":"Assessment of substrate-dependent ligand interactions at the organic cation transporter OCT2 using six model substrates","volume":"94","author":"Sandoval","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104908_bib57","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.antiviral.2020.104908_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2018.10.061","article-title":"Second generation of diazachrysenes: protection of Ebola virus infected mice and mechanism of action","volume":"162","author":"Selakovic","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104908_bib59","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104908_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104908_bib61","doi-asserted-by":"crossref","first-page":"25523","DOI":"10.1038\/srep25523","article-title":"BRAID: a unifying paradigm for the analysis of combined drug action","volume":"6","author":"Twarog","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104908_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2020.104908_bib63","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acs.molpharmaceut.8b01214","article-title":"Halogen substitution influences ketamine metabolism by cytochrome P450 2B6: in vitro and computational approaches","volume":"16","author":"Wang","year":"2019","journal-title":"Mol. Pharm."},{"issue":"2003","key":"10.1016\/j.antiviral.2020.104908_bib64","first-page":"2025","article-title":"FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 <em>in vitro<\/em>","volume":"2020","author":"Weston","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2020.104908_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00941-17","article-title":"Characterization of influenza virus pseudotyped with ebolavirus glycoprotein","volume":"92","author":"Xiao","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104908_bib66","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.molpharmaceut.8b01297","article-title":"Multiple machine learning comparisons of HIV cell-based and reverse transcriptase data sets","volume":"16","author":"Zorn","year":"2019","journal-title":"Mol. Pharm."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:34:15Z","timestamp":1759062855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220303223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":66,"alternative-id":["S0166354220303223"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104908","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Pyramax\u00ae, quinacrine and tilorone as treatments for Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104908"}}